Bioprocessing symposium to showcase biopharma and purification innovation
29 January 2026 | By
The three-day MSS2026 event takes place in September in Slovenia, with online attendance options also available.
List view / Grid view
29 January 2026 | By
The three-day MSS2026 event takes place in September in Slovenia, with online attendance options also available.
People, not platforms, will define the next era of innovation, explain Chiesi’s Executive VP of R&D Diego Ardigò and Nick Petschek, EMEA Managing Director at Kotter.
He brings 30 years of pharma industry experience to the role, principally in key manufacturing projects.
Research findings support the design of robust microbial processes for pharmaceutical products.
Named CEO of the Year at CPHI Frankfurt, the CDMO's head talks about the type of company he and his team are building.
His appointment comes as the pharma company AstraZeneca seeks to hit $80 billion revenue target by 2030.
Gains access to the company’s small molecule-targeted protein degraders to expand its oncology pipeline.
The deal will see the companies combine their respective work on CHO-MK cells and GMP-manufactured culture media.
The impurities research illustrates an approach that could offer a simpler and more flexible downstream purification process.
17 December 2025 | By Particle Measuring Systems
Join this webinar as we examine the main personnel-related factors that could lead to particle/microbial contamination risks of the product and outline practical measures that can mitigate these risks.
Progress made in the region’s approach to critical medicines and antibiotics as the EU Council and EU Parliament agree a new deal.
The US approval for the Ayrmid company’s novel transplant option Omisirge adds to its existing licence in haematological malignancy.
2 December 2025 | By Emerson
Is operational complexity limiting your performance? Discover how autonomous technologies are reducing risk and improving quality in pharma organisations.
EPR Issue 4 includes articles on manufacturing, AI/ML, vaccine development, biologics and more.
Changes proposed in the EU body’s regulatory framework aim to create a competitive and sustainable European bioeconomy.